---
title: "Poster download: Organoid monolayers: a patient-relevant platform to study intestinal barrier function, inflammatory bowel disease (IBD), and GI toxicity"
description: "Download our poster at ELRIG 2023 that highlights organoid monolayers: a patient-relevant platform to study intestinal barrier function, inflammatory bowel disease (IBD), and GI toxicity"
image: https://resources.huborganoids.nl/hubfs/post-event%20social%20ELRIG%201.jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

PRESENTED AT ELRIG 2023

# Organoid monolayers: a patient-relevant platform to study intestinal barrier function, inflammatory bowel disease (IBD), and GI toxicity

![ELRIG 2023 Poster](https://resources.huborganoids.nl/hs-fs/hubfs/assets2023/elrig-poster-2023.png?width=300&name=elrig-poster-2023.png)

Conducting comprehensive studies on the intestinal epithelial barrier has been challenging due to the absence of suitable physiologically relevant in vitro systems. Patient-derived organoids (PDOs) have emerged as a promising solution, effectively replicating cellular diversity and patient heterogeneity, providing an insightful platform for exploring the complexities of the intestinal epithelium and its responses to microbial or inflammatory challenges. This poster presents the development of biobanks consisting of patient-derived and animal models-derived organoids, as well as the applications of PDO monolayers in predicting gastrointestinal (GI) toxicity, analyzing drug transport, and advancing research in inflammatory bowel disease (IBD).

#### Download this poster to discover:

- Insights into our established biobanks of patient-derived and animal-derived organoids for toxicology research
- Key attributes of the PDO Monolayer platform, focusing on gut permeability and transport studies
- The role of PDO Monolayer in predicting gastrointestinal toxicity and facilitating advancements in IBD therapeutics

### Download our poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*